🔗 Permalink

Inventor profile of:

Alan J. Korman

City:

Piedmont, California

Country:

United States

Published Applications:

140

Last publication date:

2026-05-07

Top Assignees for applications by Alan J. Korman

The entities that hold a legal rights for patent applications filed by inventor Korman Alan J.:

BRISTOL-MYERS SQUIBB COMPANY 60 Princeton, NJ United States
Medarex, Inc. 17 Princeton, NJ United States
E.R. Squibb & Sons, L.L.C. 16 Princeton, NJ United States
ONO PHARMACEUTICAL CO., LTD. 10 Osaka, Japan
E.R. SQUIBB & SONS, L.L.C. 8 Princeton, NJ United States
Five Prime Therapeutics, Inc. 8 Thousand Oaks, CA United States
MEDAREX, L.L.C. 8 Princeton, NJ United States
E.R. Squibb & Sons, L. L. C. 4 Princeton, NJ United States
FIVE PRIME THERAPEUTICS, INC. 4 South San Francisco, CA United States
E. R. Squibb & Sons, L.L.C. 3 Princeton, NJ United States
E.R. Squibb & Sons, L. L. C. 2 Princeton, NJ United States
E. R. SQUIBB & SONS, L. L. C. 2 Princeton, NJ United States
Medarex, Inc. 2 Milpitas, CA United States
ADURO GVAX INC. 2 Berkeley, CA United States
BioSante Pharmaceuticals, Inc. 2 Lincolnshire, IL United States
N.V.Organon 1 Oss, Netherlands
Ono Pharmaceutical Co., LTD. 1 Osaka, NJ Japan
N.V. Organon 1 Oss, Netherlands
Cell Genesys, Inc. 1 South San Francisco, CA United States
ONO PHARMACEUTICAL CO., LTD. 1 Osaka-shi, Japan
Ono Pharmaceutical Co., LTD. 1 , Japan
Providence Health & Services 1 Portland, OR United States
Medarex, Inc. 1 Annandale, NJ United States
Providence Health & Services 1 Portland, OR United States

Recent patent applications by Korman Alan J.

Alan J. Korman from Piedmont, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-07

US20260125466A1

Chemistry; metallurgy

Antibodies Binding to ILT4

#2 | 2025-10-23

US20250326841A1

Chemistry; metallurgy

ANTIBODIES AGAINST TIM3 AND USES THEREOF

#3 | 2025-07-24

US20250236650A1

Chemistry; metallurgy

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

#4 | 2025-06-26

US20250206822A1

Chemistry; metallurgy

Antibodies Binding to Vista at Acidic pH

#5 | 2025-06-19

US20250197494A1

Chemistry; metallurgy

METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3

#6 | 2025-05-22

US20250163155A1

Chemistry; metallurgy

COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS

#7 | 2025-05-22

US20250163152A1

Chemistry; metallurgy

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT

#8 | 2025-05-15

US20250154254A1

Chemistry; metallurgy

HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF

#9 | 2025-04-24

US20250129166A1

Chemistry; metallurgy

Antibodies Binding to Vista at Acidic pH

#10 | 2025-04-10

US20250115664A1

Chemistry; metallurgy

ANTIBODIES AGAINST TIM3 AND USES THEREOF

#11 | 2025-03-27

US20250101100A1

Chemistry; metallurgy

ANTI-NKG2A ANTIBODIES AND USES THEREOF

#12 | 2024-06-27

US20240209083A1

Chemistry; metallurgy

ANTIBODIES AGAINST TIM3 AND USES THEREOF

#13 | 2024-05-30

US20240174749A1

Chemistry; metallurgy

METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3

#14 | 2024-05-16

US20240158524A1

Chemistry; metallurgy

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

#15 | 2024-05-02

US20240141059A1

Chemistry; metallurgy

ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

#16 | 2024-03-21

US20240092907A1

Chemistry; metallurgy

Antibodies binding to VISTA at acidic pH

#17 | 2024-02-08

US20240041995A1

Human necessities

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

#18 | 2023-11-30

US20230382992A1

Chemistry; metallurgy

Antibodies against TIM3 and uses thereof

#19 | 2023-10-12

US20230322919A1

Chemistry; metallurgy

Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof

#20 | 2023-09-14

US20230287064A1

Chemistry; metallurgy

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

#21 | 2023-08-31

US20230272100A1

Chemistry; metallurgy

ANTIBODIES AGAINST OX-40 AND USES THEREOF

#22 | 2023-08-31

US20230272079A1

Chemistry; metallurgy

Monoclonal Antibodies to Programmed Death 1 (PD-1)

#23 | 2023-06-08

US20230174647A1

Chemistry; metallurgy

Antibodies Binding to ILT4

#24 | 2023-04-13

US20230111786A1

Chemistry; metallurgy

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT

#25 | 2023-03-02

US20230061544A1

Chemistry; metallurgy

HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)

#26 | 2023-02-16

US20230051701A1

Chemistry; metallurgy

ANTIBODIES AGAINST CD73 AND USES THEREOF

#27 | 2023-02-16

US20230050665A1

Chemistry; metallurgy

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

#28 | 2022-09-08

US20220281980A1

Chemistry; metallurgy

ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF

#29 | 2022-06-30

US20220204618A1

Chemistry; metallurgy

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

#30 | 2022-06-30

US20220204612A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#31 | 2022-06-23

US20220195042A1

Chemistry; metallurgy

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

#32 | 2022-06-23

US20220195040A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#33 | 2022-06-16

US20220185892A1

Chemistry; metallurgy

Combination of Anti-LAG-3 Antibodies and Anti-PD-1 Antibodies to Treat Tumors

#34 | 2022-06-09

US20220175921A1

Human necessities

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

#35 | 2022-04-28

US20220127363A1

Chemistry; metallurgy

USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE

#36 | 2022-03-24

US20220089720A1

Chemistry; metallurgy

Antibodies against TIM3 and uses thereof

#37 | 2022-03-10

US20220073617A1

Chemistry; metallurgy

Antibodies binding to vista at acidic pH

#38 | 2021-11-25

US20210363242A1

Chemistry; metallurgy

METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3

#39 | 2021-11-04

US20210340250A1

Chemistry; metallurgy

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT

#40 | 2021-08-26

US20210261662A1

Chemistry; metallurgy

Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof

#41 | 2021-08-26

US20210261661A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#42 | 2021-08-26

US20210261660A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#43 | 2021-05-27

US20210155703A1

Chemistry; metallurgy

Anti-CD27 antibodies and uses thereof

#44 | 2021-01-21

US20210017283A1

Chemistry; metallurgy

Antibodies binding to vista at acidic pH

#45 | 2021-01-14

US20210011022A1

Physics

Anti-GITR antibodies for cancer diagnostics

#46 | 2021-01-14

US20210009692A1

Chemistry; metallurgy

Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors

#47 | 2020-12-24

US20200399385A1

Chemistry; metallurgy

Antibodies against OX-40 and uses thereof

#48 | 2020-12-10

US20200385467A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof

#49 | 2020-12-10

US20200385466A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#50 | 2020-09-24

US20200299400A1

Chemistry; metallurgy

ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

#51 | 2020-08-27

US20200268901A1

Human necessities

ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

#52 | 2020-07-23

US20200231671A1

Chemistry; metallurgy

HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF

#53 | 2020-07-02

US20200207816A1

Chemistry; metallurgy

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

#54 | 2020-06-25

US20200199226A1

Chemistry; metallurgy

Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies

#55 | 2020-06-18

US20200190186A1

Chemistry; metallurgy

Antibodies against TIM3 and uses thereof

#56 | 2020-05-07

US20200138945A1

Human necessities

Monoclonal Antibodies to Programmed Death 1 (PD-1)

#57 | 2020-04-16

US20200115463A1

Chemistry; metallurgy

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

#58 | 2020-03-12

US20200079865A1

Chemistry; metallurgy

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

#59 | 2020-03-12

US20200079848A1

Chemistry; metallurgy

Antibodies binding to ILT4

#60 | 2020-02-27

US20200062848A1

Chemistry; metallurgy

HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)

#61 | 2020-02-27

US20200062845A1

Chemistry; metallurgy

COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS

#62 | 2020-02-20

US20200055936A1

Chemistry; metallurgy

Antibodies binding to VISTA at acidic pH

#63 | 2020-01-30

US20200030425A1

Human necessities

Anti-ICOS agonist antibodies and uses thereof

#64 | 2019-12-19

US20190382491A1

Chemistry; metallurgy

TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANTI-CD137

#65 | 2019-12-19

US20190382490A1

Chemistry; metallurgy

USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE

#66 | 2019-10-17

US20190315870A1

Chemistry; metallurgy

Antibodies against MICA and/or MICB and uses thereof

#67 | 2019-10-03

US20190298816A1

Human necessities

Anti-ICOS agonist antibodies and uses thereof

#68 | 2019-09-19

US20190284293A1

Chemistry; metallurgy

COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES

#69 | 2019-09-12

US20190276539A1

Chemistry; metallurgy

HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF

#70 | 2019-09-12

US20190276538A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#71 | 2019-08-15

US20190248893A1

Chemistry; metallurgy

ANTIBODIES AGAINST TIM3 AND USES THEREOF

#72 | 2019-06-13

US20190175705A1

Human necessities

Anti-ICOS agonist antibodies and uses thereof

#73 | 2019-04-25

US20190119384A1

Chemistry; metallurgy

HUMAN CTLA-4 ANTIBODIES AND THEIR USES

#74 | 2019-04-25

US20190119381A1

Chemistry; metallurgy

FULLY HUMAN ANTIBODIES TO BTLA

#75 | 2019-03-14

US20190076515A1

Human necessities

Anti-ICOS agonist antibodies and uses thereof

#76 | 2019-02-28

US20190062456A1

Chemistry; metallurgy

Antibodies against CD73 and uses thereof

#77 | 2019-02-21

US20190055320A1

Chemistry; metallurgy

ANTIBODIES AGAINST CD73 AND USES THEREOF

#78 | 2019-02-05

US15071489

Chemistry; metallurgy

Ipilimumab variant with enhanced ADCC

#79 | 2019-01-31

US20190031763A1

Chemistry; metallurgy

Human monoclonal antibodies that bind CXCR4 and uses thereof

#80 | 2018-11-29

US20180339042A1

Human necessities

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

#81 | 2018-11-22

US20180333502A1

Human necessities

Antibodies comprising modified heavy constant regions

#82 | 2018-11-01

US20180312553A1

Chemistry; metallurgy

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

#83 | 2018-10-18

US20180298097A1

Chemistry; metallurgy

Antibodies against TIM3 and uses thereof

#84 | 2018-10-11

US20180289790A1

Human necessities

Anti-ICOS agonist antibodies and uses thereof

#85 | 2018-08-30

US20180246113A1

Physics

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

#86 | 2018-08-23

US20180237534A1

Chemistry; metallurgy

ANTIBODIES AGAINST OX40 AND USES THEREOF

#87 | 2018-06-14

US20180164321A1

Physics

Anti-GITR antibodies for cancer diagnostics

#88 | 2018-05-10

US20180127513A1

Chemistry; metallurgy

Antibodies against CD73 and uses thereof

#89 | 2018-03-08

US20180066054A1

Chemistry; metallurgy

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

#90 | 2018-01-18

US20180016336A1

Chemistry; metallurgy

Antibodies against TIM3 and uses thereof

#91 | 2018-01-04

US20180002432A1

Chemistry; metallurgy

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

#92 | 2017-10-26

US20170306035A1

Chemistry; metallurgy

Antibodies against OX40 and uses thereof

#93 | 2017-09-07

US20170253665A1

Chemistry; metallurgy

Antibodies against CD73

#94 | 2017-08-31

US20170247455A1

Chemistry; metallurgy

TREATMENT OF CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CD137 ANTIBODY

#95 | 2017-06-08

US20170158767A1

Chemistry; metallurgy

HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)

#96 | 2017-05-25

US20170145104A1

Chemistry; metallurgy

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

#97 | 2017-03-30

US20170088615A1

Chemistry; metallurgy

Monoclonal antibodies to programmed death 1 (PD-1)

#98 | 2016-12-15

US20160362495A1

Chemistry; metallurgy

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

#99 | 2016-12-01

US20160347849A1

Chemistry; metallurgy

Antibodies against OX40 and uses thereof

#100 | 2016-09-08

US20160257753A1

Chemistry; metallurgy

HUMAN CTLA-4 ANTIBODIES AND THEIR USES

InventorID:

52374 ⎘